ELAN Jan 2025 10.000 put
| Previous Close | 0.2000 |
| Open | 0.2000 |
| Bid | 0.1000 |
| Ask | 0.2000 |
| Strike | 10.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.2000 - 0.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 221 |
PR NewswireElanco Announces FDA Approval and Launch of Zenrelia™ (ilunocitinib tablets), Offering An Effective, Safe Solution in Canine Dermatology
Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has approved Zenrelia™, a safe, highly effective, and convenient once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
ReutersUS FDA approves Elanco's skin disease treatment for dogs
(Reuters) -The U.S. Food and Drug Administration has approved Elanco Animal Health's skin disease treatment for dogs, the health regulator's website showed on Thursday, sending the company's shares up 2% in afternoon trade. The oral drug, Zenrelia, aims to control pruritus, or itching, associated with allergic dermatitis and to control atopic dermatitis in dogs that are at least 12 months old. Elanco considers Zenrelia as one of its potential blockbusters.
PR NewswireElanco Provides Update on Contract Manufacturing Partner
Elanco Animal Health Incorporated (NYSE: ELAN) today provided an update on its relationship with contract manufacturing supplier, TriRx Speke Ltd (TriRx). TriRx today entered into trading administration, a formal insolvency process in the United Kingdom designed to help companies facing severe financial challenges regain stability. Administrators from FTI Consulting LLP have been appointed.
